BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28869548)

  • 1. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
    Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
    Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
    J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
    Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
    Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
    Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
    Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
    J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones.
    Lee S; Youn K; Lim G; Lee J; Jun M
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29932100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
    Narang SS; Goyal D; Goyal B
    Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
    Kumar A; Roy S; Tripathi S; Sharma A
    J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
    Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
    Chakraborty S; Kumar S; Basu S
    Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
    Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
    J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
    Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
    Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
    Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
    Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
    Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
    PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from
    Youn K; Jun M
    Nutrients; 2019 Mar; 11(3):. PubMed ID: 30893825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.